These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19674285)

  • 1. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis.
    Corey KE; Mendez-Navarro J; Gorospe EC; Zheng H; Chung RT
    J Viral Hepat; 2010 Mar; 17(3):201-7. PubMed ID: 19674285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV-infected men who have sex with men.
    Aebi-Popp K; Wandeler G; Salazar-Vizcaya L; Metzner K; Stöckle M; Cavassini M; Hoffmann M; Lüthi A; Suter F; Bernasconi E; Fehr J; Furrer H; Rauch A;
    HIV Med; 2018 Jul; 19(6):420-425. PubMed ID: 29573533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment optimization and prediction of HCV clearance in patients with acute HCV infection.
    Mangia A; Santoro R; Copetti M; Massari M; Piazzolla V; Spada E; Cappucci G; Missale G; Mottola L; Agostinacchio E; Mauro Ld; Zuccaro O; Maio P; Pellegrini F; Folgori A; Ferrari C
    J Hepatol; 2013 Aug; 59(2):221-8. PubMed ID: 23587473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.
    Kamal SM; Fouly AE; Kamel RR; Hockenjos B; Al Tawil A; Khalifa KE; He Q; Koziel MJ; El Naggar KM; Rasenack J; Afdhal NH
    Gastroenterology; 2006 Mar; 130(3):632-8. PubMed ID: 16530503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C.
    Liu CH; Liang CC; Liu CJ; Lin JW; Chen SI; Hung PH; Tsai HB; Lai MY; Chen PJ; Chen DS; Kao JH
    Clin Infect Dis; 2010 Sep; 51(5):541-9. PubMed ID: 20645865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study.
    Piroth L; Larsen C; Binquet C; Alric L; Auperin I; Chaix ML; Dominguez S; Duval X; Gervais A; Ghosn J; Delarocque-Astagneau E; Pol S;
    Hepatology; 2010 Dec; 52(6):1915-21. PubMed ID: 21064156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.
    Seeff LB; Hoofnagle JH
    Clin Liver Dis; 2003 Feb; 7(1):261-87. PubMed ID: 12691470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.
    Gerlach JT; Diepolder HM; Zachoval R; Gruener NH; Jung MC; Ulsenheimer A; Schraut WW; Schirren CA; Waechtler M; Backmund M; Pape GR
    Gastroenterology; 2003 Jul; 125(1):80-8. PubMed ID: 12851873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection.
    Cho YK; Kim YN; Song BC
    Clin Mol Hepatol; 2014 Dec; 20(4):368-75. PubMed ID: 25548743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection.
    Beinhardt S; Payer BA; Datz C; Strasser M; Maieron A; Dorn L; Grilnberger-Franz E; Dulic-Lakovic E; Stauber R; Laferl H; Aberle JH; Holzmann H; Krall C; Vogel W; Ferenci P; Hofer H
    J Hepatol; 2013 Nov; 59(5):972-7. PubMed ID: 23850880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of hepatitis C virus core antigen levels in monitoring acute hepatitis C spontaneous clearance or treatment-induced clearance.
    Zhao N; Zheng W; Wu D; Wang X; Yang W; Yuan L; Niu Z; Jiang X; Huang F; Li Z
    J Med Virol; 2018 Dec; 90(12):1787-1792. PubMed ID: 29995318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptomatic acute hepatitis C in Egypt: diagnosis, spontaneous viral clearance, and delayed treatment with 12 weeks of pegylated interferon alfa-2a.
    Sharaf Eldin N; Ismail S; Mansour H; Rekacewicz C; El-Houssinie M; El-Kafrawy S; El Aidi S; Abdel-Hamid M; Esmat G; Pol S; Fontanet A; Mohamed MK
    PLoS One; 2008; 3(12):e4085. PubMed ID: 19115010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up.
    Yu ML; Lee CM; Chen CL; Chuang WL; Lu SN; Liu CH; Wu SS; Liao LY; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Su WW; Lin CL; Yang HC; Chen PJ; Chen DS; Liu CJ;
    Hepatology; 2013 Jun; 57(6):2135-42. PubMed ID: 23322699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon for acute hepatitis C.
    Poynard T; Regimbeau C; Myers RP; Thevenot T; Leroy V; Mathurin P; Opolon P; Zarski JP
    Cochrane Database Syst Rev; 2002; 2001(1):CD000369. PubMed ID: 11869573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial.
    Deterding K; Grüner N; Buggisch P; Wiegand J; Galle PR; Spengler U; Hinrichsen H; Berg T; Potthoff A; Malek N; Großhennig A; Koch A; Diepolder H; Lüth S; Feyerabend S; Jung MC; Rogalska-Taranta M; Schlaphoff V; Cornberg M; Manns MP; Wedemeyer H;
    Lancet Infect Dis; 2013 Jun; 13(6):497-506. PubMed ID: 23523674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host and viral determinants of the outcome of exposure to HCV infection genotype 4: a large longitudinal study.
    Kamal SM; Kassim SK; Ahmed AI; Mahmoud S; Bahnasy KA; Hafez TA; Aziz IA; Fathelbab IF; Mansour HM
    Am J Gastroenterol; 2014 Feb; 109(2):199-211. PubMed ID: 24445571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute hepatitis C in Spain: a retrospective study of 131 cases.
    Pérez-Álvarez R; García-Samaniego J; Solá R; Pérez-López R; Bárcena R; Planas R; Cañete N; Manzano ML; Gutiérrez ML; Morano L; Rodrigo L
    Rev Esp Enferm Dig; 2012 Feb; 104(1):21-8. PubMed ID: 22300113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
    Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.